AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 3858894
Drug: 1-mg DST
RxNorm normalized name: DST
DrugBank: Dihydrostreptomycin (DB11512)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-mg DST
Trial: 3858894
Drug: 2-mg DST
RxNorm normalized name: DST
DrugBank: Dihydrostreptomycin (DB11512)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-mg DST
Trial: 3858894
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 1-mg and 2-mg DST with 119 semi-consecutive admissions
Trial: 30921979
Drug: Intravenous lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous lidocaine infusion (IVLI) 2 mg/minute for 4 hours
Trial: 30921979
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline solution 0.9% (Control)
Trial: 25758436
Drug: Contrast-enhanced ultrasound
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contrast-enhanced ultrasound (CEUS) used before, during and after HIFU treatment (Group A)
Trial: 25758436
Drug: No CEUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No CEUS administered (Group B)
Trial: 21051458
Drug: Medical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical treatment (rate control)
Trial: 15190528
Drug: MCC-135 5
RxNorm normalized name: Trastuzumab-MCC-DM1
DrugBank: Trastuzumab emtansine (DB05773)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: MCC-135 5 mg, twice daily
Trial: 15190528
Drug: MCC-135 25
RxNorm normalized name: Trastuzumab-MCC-DM1
DrugBank: Trastuzumab emtansine (DB05773)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: MCC-135 25 mg, twice daily
Trial: 15190528
Drug: MCC-135 50
RxNorm normalized name: Trastuzumab-MCC-DM1
DrugBank: Trastuzumab emtansine (DB05773)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: MCC-135 50 mg, twice daily
Trial: 12587476
Drug: Definitive radiotherapy
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Definitive radiotherapy only, delivered with megavoltage linear accelerator, combined with intracavitary brachytherapy in some patients, total tumor dose range 55-75 Gy
Trial: 9572815
Drug: Creatine supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine supplementation (30 g creatine + 30 g dextrose per day)
Trial: 9572815
Drug: Placebo (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (30 g dextrose per day)
Trial: 8589479
Drug: Human leukocyte
RxNorm normalized name: Human leukocyte antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human leukocyte interferon-alpha cream (2x10(6) IU/g) applied thrice daily for 5 consecutive days
Trial: 775616
Drug: Colo-rectal operations
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Colo-rectal operations
Trial: 31291984
Drug: Pharmacopuncture with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacopuncture with hominis placenta extract (PLC), administered twice a week for a total of 18 sessions over 9 weeks.
Trial: 31291984
Drug: Injections of
RxNorm normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injections of normal saline, administered at the same acupoints during the same period as PLC.
Trial: 17014060
Drug: Non-protease inhibitors
RxNorm normalized name: Protease inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-protease inhibitors (non-PIs)
Trial: 15341255
Drug: Metformin (850
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (850 mg twice a day) + Diane35 (for the first two months)
Trial: 7967853
Drug: Self-administered symptom
RxNorm normalized name: Pamprin Multi-Symptom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-administered symptom severity scale
Trial: 7967853
Drug: Self-administered functional
RxNorm normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-administered functional status scale
Trial: 7967853
Drug: Self-administered activities
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-administered activities of daily living scale
Trial: 3410484
Drug: Pyridostigmine bromide
RxNorm normalized name: Pyridostigmine Bromide
DrugBank: Pyridostigmine (DB00545)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pyridostigmine bromide (60 mg)
Trial: 3410484
Drug: Lactose (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactose (60 mg)
Trial: 29871197
Drug: Sodium pyruvate
RxNorm normalized name: Sodium Pyruvate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium pyruvate nasal spray
Trial: 17646506
Drug: 5 mL
RxNorm normalized name: WATER,INHL 5 ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mL saline (distention)
Trial: 17646506
Drug: 2 mL
RxNorm normalized name: ethanol 2 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mL (nondistention)
Trial: 16238116
Drug: Fluvastatin (Lescol)
RxNorm normalized name: fluvastatin Oral Capsule [Lescol]
DrugBank: Fluvastatin (DB01095)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluvastatin (Lescol) 40 mg once daily at bedtime for 6 weeks
Trial: 16238116
Drug: Atorvastatin (Sortis)
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atorvastatin (Sortis) 10 mg once daily at bedtime for 6 weeks
Trial: 12396958
Drug: H. pylori
RxNorm normalized name: H. PYLORI AGENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H. pylori eradication treatment with amoxicillin, clarithromycin, and omeprazole for 7 days
Trial: 7531394
Drug: G‐CSF 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G‐CSF 200 micrograms per square meter per day subcutaneously until ANC > 1,500/mm³ (group B)
Trial: 7531394
Drug: G‐CSF prophylactically
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G‐CSF prophylactically used in high-dose cytosine arabinoside regimens (group C)
Trial: 7531394
Drug: No G‐CSF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No G‐CSF used (group A)
Trial: 31577772
Drug: Rational Emotive
RxNorm normalized name: plasma protein fraction Injection [Plasmanate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rational Emotive Behavioral Therapy (REBT)
Trial: 27836862
Drug: 5-azacitidine (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-azacitidine (75 mg/m2) for 5 days prior to EOX chemotherapy (E: 50 mg/m2, O: 130 mg/m2, X: 625 mg/m2 twice daily for 21 days)
Trial: 27836862
Drug: 5-azacitidine (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-azacitidine (75 mg/m2) for 3 days prior to EOX chemotherapy
Trial: 25801556
Drug: Colistin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colistin plus ascorbic acid (2 g every 12 h)
Trial: 21865979
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil (FO) supplementation (5 mL daily)
Trial: 21865979
Drug: Sunflower oil
RxNorm normalized name: Sunflower Oil
DrugBank: Sunflower oil (DB14329)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunflower oil (SO) supplementation (5 mL daily)
Trial: 19625243
Drug: Glipizide XL,
RxNorm normalized name: GlipiZIDE XL, 5 mg oral tablet, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glipizide XL, 10 mg orally daily (G group)
Trial: 19625243
Drug: Glipizide XL,
RxNorm normalized name: GlipiZIDE XL, 5 mg oral tablet, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glipizide XL, 10 mg orally daily, plus insulin glargine, 10 U daily (G+G group)
Trial: 19625243
Drug: Both treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatment groups (G and G+G)
Trial: 17346444
Drug: 1% PLA2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% PLA2 inhibitor-containing cream
Trial: 14610134
Drug: Treatment for
RxNorm normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment for spontaneous intracranial hypotension (exact treatment not specified)
Trial: 10474118
Drug: GH therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH therapy (daily s.c. injections at a weekly dose of 8.2 mg/m(2) for 1.9-7.5 years)
Trial: 9102589
Drug: 0.5% bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% bupivacaine 1 ml (group A)
Trial: 9102589
Drug: 1% bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% bupivacaine 0.5 ml (group B)
Trial: 6352655
Drug: 0.25 g
RxNorm normalized name: AMICAR 0.25 GM/mL Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 g ceftazidime twice daily for five days
Trial: 6352655
Drug: 0.50 g
RxNorm normalized name: SALICYLIC ACID 0.50 g in 100 g TOPICAL SOAP [ORIPAN GOLD 100g]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.50 g ceftazidime twice daily for five days
Trial: 6352655
Drug: 1.00 g
RxNorm normalized name: Niacinamide 1.00 g in 50 mL TOPICAL LIQUID [by selected hyaluron day serum]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.00 g ceftazidime twice daily for five days
Trial: 31926918
Drug: Berberine 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Berberine 0.3 g twice daily
Trial: 30670262
Drug: Almond oil
RxNorm normalized name: Almond Oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Almond oil (10 ml, two times daily for 30 days)
Trial: 28629665
Drug: Tofacitinib monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tofacitinib monotherapy (5 mg twice daily)
Trial: 28629665
Drug: Tofacitinib plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tofacitinib plus methotrexate (5 mg twice daily)
Trial: 28629665
Drug: Adalimumab plus
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Adalimumab plus methotrexate (40 mg every other week)
Trial: 21735192
Drug: 5 mg/day
RxNorm normalized name: Lyllana 0.05 MG/Day Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/day Letrozole (group 1)
Trial: 21735192
Drug: 7.5 mg/day
RxNorm normalized name: nicotine 7.5 MG/Day 24 HR Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 mg/day Letrozole (group 2)
Trial: 19370533
Drug: Intermittent docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intermittent docetaxel chemotherapy (1, 2, or 3 cycles)
Trial: 19370533
Drug: Intermittent docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intermittent docetaxel chemotherapy (2 cycles)
Trial: 19370533
Drug: Intermittent docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intermittent docetaxel chemotherapy (3 cycles)
Trial: 19370533
Drug: Intermittent docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intermittent docetaxel chemotherapy
Trial: 16510768
Drug: Valproic acid
RxNorm normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Valproic acid (VPA) 250 mg twice daily
Trial: 15585154
Drug: Absorption (AP)
RxNorm normalized name: ABSORPTION BASE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Absorption (AP) group
Trial: 11214094
Drug: Weekly chloroquine
RxNorm normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly chloroquine prophylaxis
Trial: 11214094
Drug: Daily iron
RxNorm normalized name: Walgreens Multivitamin One Daily Iron-Free Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily iron and weekly folic-acid supplementation
Trial: 29391265
Drug: G‐CSF group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G‐CSF group (n = 18)
Trial: 29391265
Drug: Combination group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination group (G‐CSF + NAC) (n = 19)
Trial: 29391265
Drug: Standard medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard medical therapy group (n = 20)
Trial: 26926657
Drug: Pharmaceutical care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical care intervention (test 1 and test 2 groups)
Trial: 20662342
Drug: Nutritional program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutritional program (NUT) - 10 mg/day iron, 11 mg zinc three times a week, 10000 IU/week of vitamin A
Trial: 20662342
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone therapy (GH) - 1.26 IU/kg/day (0.042 mg/kg/day)
Trial: 18166090
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (SRP + HMT + TAT)
Trial: 16733739
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg ferrous iron (fumarate)
Trial: 16733739
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg ferrous iron (fumarate)
Trial: 16733739
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg ferrous iron (fumarate)
Trial: 16733739
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg ferrous iron (fumarate)
Trial: 16733739
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (ferritin >70 microg/l)
Trial: 10586336
Drug: Fludarabine alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fludarabine alone (25 mg/m2/d x 5 days for 6 cycles, then 20 mg/m2/day for 6 further cycles for 18 months)
Trial: 8596381
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid supplement (400 microgram/day)
Trial: 1947364
Drug: Cholinergic blockade
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholinergic blockade with 30 micrograms kg‐1 atropine administered by intravenous injection
Trial: 6357772
Drug: progabide (+/-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: progabide (+/- 30 mg/kg/day)
Trial: 31976819
Drug: Physical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical therapy home program (4 visits) during chemotherapy
Trial: 31976819
Drug: General exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General exercise during chemotherapy
Trial: 26983164
Drug: Self-reported prescribing
RxNorm normalized name: black imported fire ant allergenic extract
DrugBank: Solenopsis richteri (DB11026)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-reported prescribing of acetaminophen/paracetamol and opiates
Trial: 25867579
Drug: Clarithromycin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin (500 mg daily for eight weeks)
Trial: 20629136
Drug: 20 mg/day
RxNorm normalized name: futibatinib 20 mg/day (4 mg x 5) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg/day istradefylline
Trial: 17049679
Drug: NefTat and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NefTat and gp120(W61D) recombinant vaccine with AS02A adjuvant
Trial: 16296364
Drug: Propofol anesthesia
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol anesthesia with amino acid infusion
Trial: 16296364
Drug: Sevoflurane anesthesia
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sevoflurane anesthesia with amino acid infusion
Trial: 11979398
Drug: Pramlintide (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pramlintide (25 microg/h or 50 microg/h) administered via 5-hour intravenous infusion
Trial: 11979398
Drug: Pramlintide (30,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pramlintide (30, 100, or 300 microg) administered via subcutaneous injections 3 times daily
Trial: 11859
Drug: Cyclophosphamide (CY),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide (CY), 50 mg/kg on each of 4 successive days
Trial: 3571741
Drug: Self-control therapy
RxNorm normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-control therapy
Trial: 3571741
Drug: Behavioral problem-solving
RxNorm normalized name: Solv X
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral problem-solving therapy
Trial: 21844075
Drug: Sodium bicarbonate
RxNorm normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium bicarbonate solution and N-acetylcysteine (control group)
Trial: 12706319
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg acarbose t.i.d. for 6 weeks, followed by 100 mg acarbose t.i.d. for 12 weeks
Trial: 1754607
Drug: Piracetam (4.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piracetam (4.8 g daily for 6 weeks)
Trial: 21970852
Drug: Erlotinib (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erlotinib (oral antiepidermal growth factor receptor tyrosine kinase inhibitor)
Trial: 19894376
Drug: Chinese decoction,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chinese decoction, ligustrazin hydrochloride injection, and He‐Ne laser therapy
Trial: 19894376
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E and Vitamin C plus external application of 20% Azelaic acid cream
Trial: 12719047
Drug: bupivacaine 0.25%
RxNorm normalized name: BUPIVACAINE 0.25%/NS INJ 400ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bupivacaine 0.25% (10 mL) and morphine 0.1% (2 mL) as a bolus followed by an infusion of bupivacaine 0.25% plus morphine 0.025% (5 mL/hr)
Trial: 12719047
Drug: bupivacaine 0.25%
RxNorm normalized name: BUPIVACAINE 0.25%/NS INJ 400ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bupivacaine 0.25% (10 mL) and saline 0.9% (2 mL) as a bolus followed by an infusion of bupivacaine 0.25% (5 mL/hr)
Trial: 9010708
Drug: Itraconazole 200
RxNorm normalized name: itraconazole 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Itraconazole 200 mg daily for 4 days
Trial: 1291405
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg p.o. omeprazole
Trial: 1291405
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg i.v. omeprazole
Trial: 1291405
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg i.v. omeprazole
Trial: 6698373
Drug: Acetaminophen (2600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen (2600 mg orally 1 hour before aspirin or ethanol)
Trial: 6698373
Drug: Aspirin (1300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (1300 mg) or Ethanol (20% vol/vol)
Trial: 6698373
Drug: Indomethacin (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin (50 mg orally 12 hours and 1 hour before acetaminophen)
Trial: 19146517
Drug: Self-worth therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-worth therapy (30 minutes, once a week for 4 weeks)
Trial: 19146517
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no therapy, 30 minutes of chatting once a week for 4 weeks)
Trial: 19146517
Drug: Self-worth therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-worth therapy
Trial: 10784481
Drug: 60 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 g/day of glycine added to clozapine
Trial: 9075807
Drug: N(G)-monomethyl-L-arginine (NO-synthase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N(G)-monomethyl-L-arginine (NO-synthase inhibitor)
Trial: 9075807
Drug: L-arginine (NO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-arginine (NO precursor)
Trial: 3703632
Drug: Human milk
RxNorm normalized name: HUMAN MILK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human milk supplemented with human milk protein (0.9 g/dL)
Trial: 3703632
Drug: Human milk
RxNorm normalized name: HUMAN MILK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human milk supplemented with medium-chain triglycerides (1 g/dL)
Trial: 10907343
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy of bifonazole (Mycospor cream) + 10% urea ointment (Urepearl) (group I)
Trial: 10907343
Drug: Occlusive dressing
RxNorm normalized name: DSG Pak with Occlusive Dressing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Occlusive dressing therapy with bifonazole (Mycospor cream) + 10% urea ointment (Urepearl) (group II)
Trial: 8054072
Drug: Intermittent transdermal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent transdermal application of nitroglycerin (15 hours/day)
Trial: 8054072
Drug: Continuous transdermal
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous transdermal application of nitroglycerin (24 hours/day)
Trial: 770083
Drug: 800 mg
RxNorm normalized name: bran 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg azapropazone per day